BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Press Releases

  Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024

  July 26, 2024

   · 

  1 min read
• Press Releases

  Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds

  July 26, 2024

   · 

  4 min read
• Press Releases

  Genetic Technologies Strategic Restructure Driving USA Sales Growth

  July 26, 2024

   · 

  7 min read
• Press Releases

  OmniGuide Holdings Announces Successful Completion of Patient Study for Revolutionary iSTONE(TM) Laser-Guided Lithotripsy Technology

  July 26, 2024

   · 

  2 min read
• Press Releases

  CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer

  July 26, 2024

   · 

  10 min read
• 

  Weight loss

  Roche to Accelerate Development of Obesity Assets from $2.7B Carmot Buy

  Encouraged by the potential of the weight-loss candidates acquired from Carmot Therapeutics, Roche will speed up the development of its obesity programs, seeking to differentiate itself in the market.

  July 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Adcomms

  FDA Adcomm Calls for Changes in Perioperative Lung Cancer Trials

  The FDA’s Oncologic Drugs Advisory Committee on Thursday strongly supported changing clinical trials for non-small cell lung cancer drugs given in the perioperative setting, pointing out the need for a more nuanced approached to treatments before and after surgery.

  July 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Earnings

  Argenx’s Strong Q2 Sales Reinvigorate Clinical Plans for Vyvgart

  The company’s FcRn inhibitor Vyvgart grew 17% quarter-over-quarter, reigniting confidence it will hit its ambitious goals despite a string of clinical setbacks in recent months.

  July 26, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer’s Trial

  July 26, 2024

   · 

  8 min read
• Press Releases

  OneMedNet Announces $4.6 Million Private Placement

  July 26, 2024

   · 

  5 min read